Search
for

    Glossary Janus Kinase 2

    enzyme involved in cell signaling and blood cell production

    Janus Kinase 2 (JAK2) is an enzyme that plays a crucial role in the signaling pathways of various types of cells, including those involved in the immune system and blood cell production. Mutations in the JAK2 gene are often associated with certain blood disorders and cancers, such as polycythemia vera and essential thrombocythemia, making it a significant target for medical research and treatment development.

    Related Terms

    Research 10 of 1000+

    1. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results Journal of the American Academy of Dermatology · 2021 · 138 citations
    2. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients Journal of the American Academy of Dermatology · 2017 · 48 citations
    3. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial Journal of the American Academy of Dermatology · 2025 · 2 citations
    4. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study Journal of The American Academy of Dermatology · 2021 · 66 citations
    5. Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata JAAD case reports · 2019 · 32 citations
    6. At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors JAAD case reports · 2020 · 4 citations
    7. SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES International Journal of Innovative Technologies in Social Science · 2025
    8. Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata British Journal of Dermatology · 2024 · 23 citations
    9. Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy JAAD Case Reports · 2023 · 7 citations
    10. 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1) Journal of Investigative Dermatology · 2019 · 5 citations
    All research results →

    Learn 3

    1. Baricitinib JAK inhibitor pill used for severe alopecia areata
    2. Tofacitinib JAK inhibitor pill, an immune-system drug
    3. Alopecia Areata autoimmune disorder causing patchy hair loss

    Community

    — no results

    Try a deeper search in community →